Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant exchange rates), mainly as a result of
Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (around $1.51 billion), however sales increased by 5.5% to 1.189 trillion yen. Actos
Pfizer have released a reasonable set of financials despite the effects of generic competition to their cholesterol blockbuster drug, Lipitor. Fourth-quarter net income soared to $6.32 billion, up from $1.44 billion in the like-for-like quarter of the previous year. The net income was boosted by the sale of their nutrition business to Nestle for $11.85
Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding campaign that will guide the transition of their facilities, operations and commercial
Allergan have agreed to pay $25 per share in a bid to purchase Mountain View’s neurology group MAP Pharmaceuticals. The per share cash offer signifies a 60% premium over MAP’s closing stock price on January 22nd, and is equal to roughly $958 million. The merger agreement, which is expected to complete during the first or
Johnson & Johnson have announced an 8% rise in sales for their fourth quarter, aided by strong results from their pharmaceutical division. The group net income for the quarter was $2.57 billion, in comparison to $218 million in the fourth quarter of the previous year, when net income was affected by charges of $2.86 billion.
A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014. It will help cover successful new Individual Patient Treatment Requests for drugs that target rare
Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therapeutics,” which they call Accurins. The partners are planning
Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors – Abbott/Eisai’s Humira and Janssen/Merck/Mitsubishi Tanabe’s Simponi – and two novel therapies –
We would like to wish all our clients and candidates a very merry Christmas and a happy new year! Thank you for your business in 2012. We look forward to working with you in 2013! Only Medics will be closed from the afternoon of the 24th December 2012 until the 2nd January 2013. If you
